邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

西藏地区藏族人群胃癌组织中H3K27me3表达水平及其临床意义

罗含欢,  师杰,  边巴扎西,  杨旭,  尼玛卓玛,  王倩,  李梅,  王寒,  廖瑞倩,  次仁曲珍

downloadPDF
文章导航 > 协和医学杂志  > 2022 >  13(6): 1088-1093
罗含欢, 师杰, 边巴扎西, 杨旭, 尼玛卓玛, 王倩, 李梅, 王寒, 廖瑞倩, 次仁曲珍. 西藏地区藏族人群胃癌组织中H3K27me3表达水平及其临床意义[J]. 协和医学杂志, 2022, 13(6): 1088-1093. doi: 10.12290/xhyxzz.2021-0727
引用本文: 罗含欢, 师杰, 边巴扎西, 杨旭, 尼玛卓玛, 王倩, 李梅, 王寒, 廖瑞倩, 次仁曲珍. 西藏地区藏族人群胃癌组织中H3K27me3表达水平及其临床意义[J]. 协和医学杂志, 2022, 13(6): 1088-1093. doi: 10.12290/xhyxzz.2021-0727
shu
LUO Hanhuan, SHI Jie, BIANBA Zhaxi, YANG Xu, NIMA Zhuoma, WANG Qian, LI Mei, WANG Han, LIAO Ruiqian, CIREN Quzhen. Expression of H3K27me3 in Tibetan Patients with Gastric Cancer and Its Significance[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 1088-1093. doi: 10.12290/xhyxzz.2021-0727
Citation: LUO Hanhuan, SHI Jie, BIANBA Zhaxi, YANG Xu, NIMA Zhuoma, WANG Qian, LI Mei, WANG Han, LIAO Ruiqian, CIREN Quzhen. Expression of H3K27me3 in Tibetan Patients with Gastric Cancer and Its Significance[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 1088-1093. doi: 10.12290/xhyxzz.2021-0727
shu

西藏地区藏族人群胃癌组织中H3K27me3表达水平及其临床意义

doi: 10.12290/xhyxzz.2021-0727
  • 1.

    西藏自治区人民医院病理科，拉萨 850000

  • 2.

    中国医学科学院北京协和医院病理科，北京 100730

  • 3.

    西藏自治区人民医院普外科，拉萨 850000

  • 4.

    中国医学科学院北京协和医院肝脏外科，北京 100730

基金项目: 

西藏自治区自然科学基金组团式援藏医学项目 XZ2017ZR-ZY33

详细信息
    通讯作者:

    师杰, E-mail：shijie@pumch.cn

  • 中图分类号: R365

Expression of H3K27me3 in Tibetan Patients with Gastric Cancer and Its Significance

  • 1.

    Department of Pathology, Tibet Autonomous Region People's Hospital, Lhasa 850000, China

  • 2.

    Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 3.

    Department of General Surgery, Tibet Autonomous Region People's Hospital, Lhasa 850000, China

  • 4.

    Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

Funds: 

Tibet Natural Science Funding Committee Grant XZ2017ZR-ZY33

More Information

    摘要
  • 摘要:   目的  探究H3K27me3在西藏地区藏族人群胃癌组织中的表达水平及其与临床、病理特征的相关性。  方法  回顾性收集2019年8月至2021年8月西藏自治区人民医院藏族胃癌患者及同期藏族非胃癌患者的临床与病理资料。采用免疫组化法检测胃癌患者手术切除的肿瘤组织、癌旁正常胃黏膜组织及非胃癌患者正常胃黏膜组织中H3K27me3表达情况，并比较不同临床与病理特征胃癌患者之间H3K27me3表达差异。  结果  共入选符合纳入和排除标准的藏族胃癌患者54例，藏族非胃癌患者55例。H3K27me3定位于细胞核, 阳性表达时细胞核呈棕黄色颗粒状着色。胃癌组织中H3K27me3高表达率显著高于癌旁正常胃黏膜组织[64.8%(35/54)比29.6%(16/54)，P＜0.001]和非胃癌患者正常胃黏膜组织[64.8%(35/54)比34.5%(19/55)，P=0.002]，癌旁正常胃黏膜组织中H3K27me3高表达率与非胃癌患者正常胃黏膜组织无显著差异(P=0.683)。H3K27me3表达水平在不同年龄、性别及Lauren分型、分化程度、浸润深度、肿瘤最大径、TNM分期等胃癌患者之间均无显著差异(P均＞0.05)。  结论  西藏地区藏族人群胃癌组织中H3K27me3表达水平显著增高，暂未发现H3K27me3表达水平与藏族胃癌患者临床及病理特征具有相关性。
    Abstract:   Objective  To investigate the expression and its significance of H3K27me3 in Tibetan patients with gastric cancer.  Methods  Clinical and pathological data were retrospectively collected from Tibetan patients with gastric cancer in the Tibet Autonomous Region People's Hospital from August 2019 to August 2021 and Tibetan non-gastric cancer patients during the same period. The expression of H3K27me3 in gastric cancer tissues, corresponding adjacent normal gastric mucosa and normal gastric mucosa of Tibetan patients with non-gastric cancer tissues was detected by immunohistochemical method, and the differences of H3K27me3 expression between gastric cancer patients with different clinical and pathological characteristics was compared.  Results  A total of 54 Tibetan gastric cancer patients and 55 Tibetan non-gastric cancer patients who met the inclusion and exclusion criteria were enrolled. H3K27me3 was localized in the nucleus, and the nucleus showed brownish-yellow granular staining when positively expressed. The high expression rate of H3K27me3 in gastric cancer tissues was significantly higher than that in adjacent normal gastric mucosa tissue[64.8%(35/54) vs. 29.6%(16/54), P < 0.001]and normal gastric mucosal tissue of Tibetan patients with non-gastric cancer[64.8%(35/54) vs. 34.5%(19/55), P=0.002], and the high expression rate of H3K27me3 in the adjacent normal gastric mucosa tissue was not significantly different from that in normal gastric mucosal tissue of Tibetan patients with non-gastric cancer(P=0.683). H3K27me3 expression in gastric cancer tissues was not related to gender, age, degree of differentiation, depth of invasion, maximum tumor size, Lauren's classification, lymph node metastasis, vascular and nerve invasion and TNM stage.  Conclusions  H3K27me3 is highly expressed in gastric cancer tissues of Tibetan people in Tibet. There is no significant difference in H3K27me3 positive expression cells in adjacent tissues and normal gastric mucosa. The significance of H3K27me3 in Tibetan patients with gastric cancer is uncertain and requires further investigations.
    作者贡献：罗含欢负责试验设计、免疫组化结果判读及论文撰写；师杰负责免疫组化结果判读和论文修订；杨旭进行数据统计学分析；边巴扎西、尼玛卓玛、王倩、王寒、廖瑞倩、次仁曲珍、李梅负责临床病理资料收集、免疫组化制片。
    利益冲突：所有作者均声明不存在利益冲突
    • HTML全文

  • 图  1  H3K27me3蛋白在胃癌组织中表达的免疫组化图(EnVision, ×200)

    A.高表达；B.低表达

    下载: 全尺寸图片 幻灯片

    图  2  H3K27me3蛋白在癌旁正常胃黏膜组织中表达的免疫组化图(EnVision，×100)

    A. 高表达；B. 低表达

    下载: 全尺寸图片 幻灯片

    图  3  H3K27me3蛋白在非胃癌患者正常胃黏膜组织中表达的免疫组化图(EnVision，×100)

    A. 高表达；B. 低表达

    下载: 全尺寸图片 幻灯片

    表  1  不同临床与病理特征西藏地区藏族胃癌患者H3K27me3表达情况比较[n(%)]

    指标 低表达(n=19) 高表达(n=35) P值
    年龄 0.128
      ≤60岁 16(84.2) 22(62.9)
      ＞60岁 3(15.8) 13(37.1)
    性别 ＞0.999
      男 13(68.4) 24(68.6)
      女 6(31.6) 11(31.4)
    Lauren分型 0.723
      肠型 6(31.6) 15(42.9)
      弥漫型 7(36.8) 11(31.4)
      混合型 6(31.6) 9(25.7)
    分化程度 0.388
      中-高分化 10(52.6) 13(37.1)
      低分化 9(47.4) 22(62.9)
    浸润深度 0.506
      pT1+pT2 6(31.6) 7(20.0)
      pT3+pT4 13(68.4) 28(80.0)
    肿瘤最大径 0.263
      ≤4 cm 6(31.6) 17(48.6)
      ＞4 cm 13(68.4) 18(51.4)
    脉管侵犯 0.577
      是 7(36.8) 16(45.7)
      否 12(63.2) 19(54.3)
    神经侵犯 0.760
      是 11(57.9) 23(65.7)
      否 8(42.1) 12(34.3)
    淋巴结转移 0.534
      是 12(63.2) 26(74.3)
      否 7(36.8) 9(25.7)
    TNM分期 0.394
      Ⅰ~Ⅱ期 11(57.9) 15(42.9)
      Ⅲ~Ⅳ期 8(42.1) 20(57.1)
    下载: 导出CSV
    • 参考文献(20)
  • [1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71: 209-249. doi:  10.3322/caac.21660
    [2] 旦增, 李康, 王中华, 等. 拉萨地区社区人群的胃癌流行病学特征[J]. 世界华人消化杂志, 2013, 21: 2104-2108. https://www.cnki.com.cn/Article/CJFDTOTAL-XXHB201321029.htm

    Dan Z, Li K, Wang ZH, et al. Epidemiological features of gastric cancer in a community population in Lhasa[J]. Shijie Huaren Xiaohua Zazhi, 2013, 21: 2104-2108. https://www.cnki.com.cn/Article/CJFDTOTAL-XXHB201321029.htm
    [3] Kurdistani SK. Histone modifications in cancer biology and prognosis[J]. Prog Drug Res, 2011, 67: 91-106.
    [4] Bates SE. Epigenetic Therapies for Cancer[J]. N Engl J Med, 2020, 383: 650-663. doi:  10.1056/NEJMra1805035
    [5] Xiao W, Zhou Q, Wen X, et al. Small Molecule Inhibitors Overcome Epigenetic Reprogramming for Cancer Therapy[J]. Front Pharmacol, 202, 12: 702360.
    [6] Nam NH, Huong TL, Dung do TM, et al. Novel isatin-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents[J]. Eur J Med Chem, 2013, 70: 477-486. doi:  10.1016/j.ejmech.2013.10.045
    [7] Luu T, Frankel P, Beumer J H, et al. Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial[J]. Cancer Chemother Pharmacol, 2019, 84: 1201-1208. doi:  10.1007/s00280-019-03955-7
    [8] Imai Y, Hirano M, Kobayashi M, et al. HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action[J]. Cancers (Basel), 2019, 11: 475. doi:  10.3390/cancers11040475
    [9] Zang H, Qian G, Zong D, et al. Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat(LBH589)[J]. Cancer, 2020, 126: 2024-2033. doi:  10.1002/cncr.32744
    [10] Tanimoto A, Takeuchi S, Arai S, et al. Histone deacety-lase 3 inhibition overcomes BIM deletion polymorphism-mediated osimertinib resistance in EGFR-Mutant lung cancer[J]. Clin Cancer Res, 2017, 23: 3139-3149. doi:  10.1158/1078-0432.CCR-16-2271
    [11] Zhang L, Zhong K, Dai Y, et al. Genome-wide analysis of histone H3 lysine 27 trimethylation by ChIP-chip in gastric cancer patients[J]. J Gastroenterol, 2009, 44: 305-312. doi:  10.1007/s00535-009-0027-9
    [12] Huang H, Xie L, Feng X, et al. An integrated analysis of DNA promoter methylation, microRNA regulation, and gene expression in gastric adenocarcinoma[J]. Ann Transl Med, 2021, 9: 1414. doi:  10.21037/atm-21-3211
    [13] Li Y, Guo D, Sun R, et al. Methylation Patterns of Lys9 and Lys27 on Histone H3 Correlate with Patient Outcome in Gastric Cancer[J]. Dig Dis Sci, 2019, 64: 439-446. doi:  10.1007/s10620-018-5341-8
    [14] WHO Classification Tumours Editorial Board. WHO classification of tumours of digestive system[M]. Lyon: LARC Press, 2019.
    [15] Samal S, Patnaik A, Sahu F, et al. Altered expression of epigenetic modifiers EZH2, H3K27me3, and DNA methyltransferases in meningiomas-prognostic biomarkers for routine practice[J]. Folia Neuropathol, 2020, 58: 133-142. doi:  10.5114/fn.2020.96970
    [16] 高福利, 吕瑛, 曹俊, 等. H3K27me3在胃癌中的表达及其临床意义[J]. 世界华人消化杂志, 2011, 19: 3597-3602. https://www.cnki.com.cn/Article/CJFDTOTAL-XXHB201135013.htm

    GaoFL, LYU Y, Cao J, et al. Significance of H3K27me3 expression in gastric cancer[J]. Shijie Huaren Xiaohua Zazhi, 2011, 19: 3597-3602. https://www.cnki.com.cn/Article/CJFDTOTAL-XXHB201135013.htm
    [17] He LJ, Cai MY, Xu GL, et al. Prognostic significance of overexpression of EZH2 and H3K27me3 proteins in gastric cancer[J]. Asian Pac J Cancer Prev, 2012, 13: 3173-3178. doi:  10.7314/APJCP.2012.13.7.3173
    [18] 高恩惠, 刘丹, 陈洁, 等. H3K27me3在肿瘤中的表达及其应用[J]. 中国新药与临床杂志, 2021, 40: 406-410. https://www.cnki.com.cn/Article/CJFDTOTAL-XYYL202106002.htm

    Gao EH, Liu D, Chen J, et al. Expression of H3K27me3 in tumors and its application[J]. Zhongguo Xinyao Yu Linchuang Zazhi, 2021, 40: 406-410. https://www.cnki.com.cn/Article/CJFDTOTAL-XYYL202106002.htm
    [19] Hong F, Zhao M, Zhang L, et al. Inhibition of Ezh2 in vitro and the decline of Ezh2 in developing midbrain promote dopami-nergicneurons differentiation through modifying H3K27me3[J]. Stem Cells Dev, 2019, 28: 649-658. doi:  10.1089/scd.2018.0258
    [20] 张宁, 曾智, 阎丽萍, 等. 幽门螺杆菌感染与胃癌中PRC2和H3K27me3的表达关系[J]. 临床研究与应用杂志, 2018, 45: 667-672. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZL201813006.htm

    Zhang N, Zeng Z, Yan LP, et al. Relationship between Helicobacter pylori infection and the expression of PRC2 and H3K27me3 in gastric cancer[J]. Linchuang Yanjiu Yu Yingyong Zazhi, 2018, 45: 667-672. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZL201813006.htm
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
图(3) / 表(1)
计量
  • 文章访问数:  283
  • HTML全文浏览量:  88
  • PDF下载量:  16
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-11-02
  • 录用日期:  2021-12-13
  • 刊出日期:  2022-11-30

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计

    x 关闭 永久关闭

    【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！